Mesa Laboratories, Inc. (MLAB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 118 | 134 | 184 | 219 | 216 | 241 | 249 | 250 |
| Operating profit | $m | 19 | 22 | ||||||
| Net profit | $m | 2 | 3 | 2 | 1 | -254 | -2 | 7 | 5 |
| EPS reported | $ | 1.21 | 0.84 | ||||||
| Operating cashflow per share | $ | 7.77 | 9.84 | ||||||
| Capex per share | $ | 0.59 | 0.08 | ||||||
| FCF per share | $ | 7.18 | 9.92 | ||||||
| Free cash flow | $m | 40 | 56 | ||||||
| Net debt | $m | 125 | 55 | ||||||
| Book value equity | $m | 186 | 189 | ||||||
| Book value per share | $ | 33.47 | 32.79 | ||||||
| Number of shares | m | 5.57 | 5.76 | ||||||
| DPS (TTM paid) | $ | 0.48 | 0.64 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 17.68 | 159.57 | ||||||
| P/B LTM | x | 2.62 | 3.41 | ||||||
| P/S LTM | x | 2.94 | 2.58 | ||||||
| P/FCF LTM | x | 12.32 | 11.48 | ||||||
| EV/EBITDA LTM | x | 7.65 | 19.68 | ||||||
| EV/Sales LTM | x | 2.47 | 2.66 | ||||||
| Earnings Yield LTM | % | +9.98% | +0.63% | ||||||
| FCF Yield | % | +8.12% | +8.71% | ||||||
| Quality | |||||||||
| ROE | % | +3.60% | +2.59% | ||||||
| ROIC | % | +2.76% | +3.05% | ||||||
| Operating margin | % | +7.43% | +9.00% | ||||||
| Gross margin | % | +63.53% | +65.99% | ||||||
| FCF/Sales | % | +15.89% | +22.47% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +3.38% | +15.51% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -6.45% | +35.02% | ||||||
| Operating Profit Growth | % | +13.31% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.72% | +0.60% | ||||||
| Dividend Growth | % | -25.00% | 0.00% | ||||||
| Payout Ratio | % | +52.32% | +75.12% | ||||||
| FCF/Debt | x | 0.23 | 0.55 | ||||||
| Net Debt/EBITDA | x | 4.02 | 1.74 | ||||||
| EBIT/Net interest | x | 1.73 | 2.07 | ||||||
| Net debt/market cap | % | +31.07% | +16.64% | ||||||
| Net debt/Equity | x | 0.67 | 0.29 | ||||||
| Gross debt/equity | x | 0.91 | 0.54 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free